Regeneron Pharmaceuticals reports $5.12 billion revenue for quarter ended September 30, 2026, up 36.3%
Regeneron Pharmaceuticals reported revenue of $5.12 billion for the quarter ended September 30, 2026, an increase of 36.3% from the same quarter a year earlier ($3.75 billion).
For the same period it posted net income of $1.95 billion, up 33.5%, or $18.45 per diluted share (13.62 a year earlier).
That is a net margin of 38.1%.
On Sanad's AAOIFI Standard 21 screen, Regeneron Pharmaceuticals is currently questionable: interest-bearing debt is 2.7% of market capitalisation (limit 30%), and impure income is 4.4% of revenue (limit 5%).
Is Regeneron Pharmaceuticals halal?
See the full AAOIFI screening of Regeneron Pharmaceuticals
See the full AAOIFI screening of Regeneron Pharmaceuticals
Source: 10-Q filed with the U.S. Securities and Exchange Commission on October 30, 2026. View the filing. Figures are as reported in the filing. This is information, not investment advice.